Dishman Carbogen Amcis has released its audited financial results for the quarter and year ended March 31, 2026. The company reported a significant increase in revenue for both the fourth quarter and the full fiscal year, driven by strong performance across its CDMO and Marketable Molecules segments. Management highlighted that the increase in CDMO revenue was primarily driven by higher commercial revenue and development revenue from late Phase III molecules, while growth in the Marketable Molecules segment was attributed to increased supplies of Vitamin D analogues.

Q4 FY26 Performance

For the quarter ended March 31, 2026, the company recorded a net revenue of ₹8,514 mn, an increase of 18.9% compared to ₹7,163 mn in the same period of the previous year. The CDMO segment contributed ₹6,909 mn to the revenue, while Marketable Molecules contributed ₹1,605 mn. EBITDA for the quarter stood at ₹1,630 mn, with a margin of 19.1%, compared to an EBITDA of ₹1,527 mn and a margin of 21.3% in Q4 FY25.

FY26 Annual Results

For the full fiscal year FY26, net revenue grew by 8.1% to ₹29,319 mn from ₹27,115 mn in FY25. The CDMO segment revenue for the year was ₹24,413 mn, and Marketable Molecules revenue was ₹4,906 mn. The company achieved an EBITDA of ₹5,656 mn for FY26, translating to a margin of 19.3%, an improvement from the 17.3% margin recorded in the previous year.

Financial Metrics

The following table summarizes the key financial metrics for the quarter and full year:

Operational Highlights

During the earnings conference call held on May 20, 2026, management noted that the company secured more than 10 late-phase projects, including PPQ campaigns. The Specialties business unit reported strong Vitamin D and analogue sales with high margins, supported by an optimized supplier base. The company initiated cost-control measures and increased its sales force across sites to attract more products and customers. Additionally, the Board approved a proposal for a long-term external commercial borrowing from a promoter entity to repay high-cost debt in India, subject to regulatory and shareholder approvals.

Dishman Carbogen Amcis Limited announced on 5 May 2026 that its wholly-owned subsidiary, CARBOGEN AMCIS (Shanghai) Co. Ltd., has successfully completed an unannounced Good Manufacturing Practice (GMP) inspection by China's National Medical Products Administration (NMPA) at its Shanghai facility. The disclosure was made under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Inspection Overview

The unannounced inspection was conducted on 14 April 2026 and encompassed a comprehensive on-site assessment of the Shanghai facility's operations. Key details of the inspection are summarised below:

The inspection covered the following areas:

• API manufacturing processes and operations
• Quality control laboratories
• Documentation practices
• Overall quality management systems
• Site's Quality System readiness

The inspection concluded without observations, and no issues requiring formal explanation were identified. Recommendations were provided to support ongoing continuous improvement.

Leadership Remarks

Senior officials from CARBOGEN AMCIS commented on the significance of the outcome.

Stephanie Schlienger, V.P. Quality & Compliance of CARBOGEN AMCIS, stated: "This outcome reflects the high level of preparedness and expertise demonstrated by our Shanghai team, as well as the strength and maturity of our Quality System. The successful completion of an unannounced inspection with no observations underlines our commitment to maintaining the highest GMP standards across all aspects of our operations."

Simone Maggi, Site Quality Head of CARBOGEN AMCIS Shanghai, noted: "For the Shanghai site, the significance of this inspection lies in the fact that it was unannounced. Such inspections test the system as it operates in routine conditions, and this result confirms both the consistency of GMP execution across the site and the readiness and competence of our team."

Stephan Fritschi, CEO of CARBOGEN AMCIS, added: "Successfully completing an unannounced NMPA inspection with no observations is a significant achievement and a strong validation of our global quality culture. It demonstrates our ability to consistently meet rigorous regulatory expectations and reinforces confidence in our Shanghai site as a reliable partner for our customers worldwide."

Role of the Shanghai Facility

The Shanghai facility plays a key role within CARBOGEN AMCIS' global network, supporting API manufacturing and process development activities. The site's successful inspection outcome acknowledges its capability to deliver high-quality services in line with international regulatory requirements. CARBOGEN AMCIS is a leading service provider offering drug development and commercialization services to the pharmaceutical and biopharmaceutical industries across all stages of clinical development and product life cycle. Dishman Carbogen Amcis Limited, headquartered in Ahmedabad, India, is a global outsourcing partner for the pharmaceutical industry, with operations across Europe, China, and India.